Insulin aspart (IAsp) has been used in patients for more than a decade. A plethora of data is available, from clinical trials, to document its efficacy and safety and suggest that IAsp is a favorable choice to be used in a basal-bolus regimen. The A1chieve@ was a non-interventional study that explored the safety and effectiveness of initiating or switching to
insulin analogues in routine clinical practice in more than 60,000 patients from 28 different countries. In this manuscript, we discuss the findings from the subgroup of the Indian cohort who were treated with
insulin aspart (IAsp), in addition to a basal
insulin analogue (
insulin detemir, IDet). In a cohort of 343, who were on IAsp + IDet, 175 (51%) were
insulin naive and 168 (49%) had been on
insulin therapy earlier. Glycaemic parameters were high at baseline. Mean HbA1c was 9.3% in them and was comparable in both
insulin naive and
insulin experienced groups. After 24 weeks of
therapy with IAsp + basal
insulin, there were reductions in HbA1c in both the
insulin naive group, (-1.6) and
insulin experienced group (-1.5). Fasting plasma
glucose (FPG) and postprandial plasma
glucose (PPG) levels were also reduced significantly from baseline (-77 and - 110 mg/dL, respectively, p < 0.001). Overall, hypoglycaemia decreased from 0.97 (baseline) to 0.18 events/patient years (24 weeks). There was also an increase in quality of life score as evaluated by EQ-5D questionnaire. Addition of IAsp with a basal
insulin in patients with poor glycaemic control leads to an improvement in glycaemic profile with no major hypoglycaemia or clinically significant
weight gain along with an improvement in the quality of life in patients with
type 2 diabetes.